Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Organon & Co. Common Stock
(NY:
OGN
)
13.70
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Organon & Co. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Today 8:00 EDT
From
Organon & Co.
Via
Business Wire
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
September 14, 2026
From
Organon & Co.
Via
Business Wire
This House of Representative Just Sold Up To $30K In Organon Stock
↗
August 13, 2026
A report on August 12, 2026 shows that Representative Kevin Hern from Oklahoma sale stock in Organon (NYSE:OGN), valued between $2,002 and $30,000. According to the August filing, the transaction...
Via
Benzinga
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
August 11, 2026
From
Organon & Co.
Via
Business Wire
Organon Announces Quarterly Dividend
July 31, 2026
From
Organon & Co.
Via
Business Wire
New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
July 24, 2026
From
Organon & Co.
Via
Business Wire
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
↗
July 23, 2026
Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to...
Via
MarketBeat
Topics
Stocks
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
July 16, 2026
From
Organon & Co.
Via
Business Wire
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
July 07, 2026
From
Organon & Co.
Via
Business Wire
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
June 24, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
June 22, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
June 22, 2026
From
Organon & Co.
Via
Business Wire
Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders
June 16, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)
June 16, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
June 10, 2026
From
Organon & Co.
Via
Business Wire
Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders
June 09, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), SUNation Energy, Inc. (Nasdaq – SUNE), Organon & Co. (NYSE – OGN), Taylor Morrison Home Corporation (NYSE – TMHC)
June 09, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Organon to Present New Research on Access and Value at ISPOR 2026
May 15, 2026
From
Organon & Co.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)
May 14, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders
May 06, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether SLNO, OGN, RMAX, XOMA are Obtaining Fair Deals for their Shareholders
May 05, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders
May 05, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
May 05, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether AVNS, OGN, ESQ, VRE are Obtaining Fair Deals for their Shareholders
May 05, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates
April 30, 2026
Pharmaceutical company Organon (NYSE:OGN) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 3.5% year on year to $1.46 billion. Its ...
Via
StockStory
Topics
Artificial Intelligence
Organon Reports Results for the First Quarter Ended March 31, 2026
April 30, 2026
From
Organon & Co.
Via
Business Wire
Organon Cancels First Quarter Earnings Call
April 29, 2026
From
Organon & Co.
Via
Business Wire
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
April 28, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders
April 27, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal
↗
April 27, 2026
Today, April 27, 2026, a jumbo all-cash buyout and merger-arb dynamics put Organon in focus.
Via
The Motley Fool
Topics
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
